Holen Sie sich die Stockscreener-App
2.56
1.59%
0.04
Handel nachbörslich:
2.55
-0.01
-0.39%
Schlusskurs vom Vortag:
$2.52
Offen:
$2.65
24-Stunden-Volumen:
1.24M
Relative Volume:
1.19
Marktkapitalisierung:
$277.33M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-4.9231
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+9.40%
1M Leistung:
+37.63%
6M Leistung:
+77.78%
1J Leistung:
+22.49%
1-Tages-Spanne:
$2.40
$2.70
1-Wochen-Bereich:
$2.24
$2.70
52-Wochen-Spanne:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Vergleichen Sie ACRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.56 | 273.00M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-05-28 | Eingeleitet | Wedbush | Outperform |
| 2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Will Aclaris Therapeutics Inc. stock outperform international peersTrade Ideas & Risk Managed Investment Entry Signals - newser.com
Key resistance and support levels for Aclaris Therapeutics Inc.2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - newser.com
Understanding Aclaris Therapeutics Inc.’s price movement2025 Top Gainers & High Yield Stock Recommendations - newser.com
Applying chart zones and confluence areas to Aclaris Therapeutics Inc.Dollar Strength & AI Enhanced Execution Alerts - newser.com
Will Aclaris Therapeutics Inc. stock deliver shareholder valueJuly 2025 Weekly Recap & Fast Gain Stock Trading Tips - newser.com
Can Aclaris Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Selloffs & AI Enhanced Trading Alerts - newser.com
Risk adjusted return profile for Aclaris Therapeutics Inc. analyzedStop Loss & Fast Momentum Entry Tips - newser.com
Statistical indicators supporting Aclaris Therapeutics Inc.’s strengthWatch List & Long Hold Capital Preservation Plans - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock is a must watch tickerPortfolio Update Summary & AI Forecasted Stock Moves - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock gets analyst attentionPortfolio Update Report & Proven Capital Preservation Methods - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock hit Wall Street targetsWeekly Profit Report & Fast Moving Stock Watchlists - newser.com
How Aclaris Therapeutics Inc. (8AT) stock performs during market turbulenceJuly 2025 News Drivers & Fast Entry Momentum Alerts - newser.com
Using Python tools to backtest Aclaris Therapeutics Inc. strategiesJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Why Aclaris Therapeutics Inc. stock attracts global investorsMarket Sentiment Review & Verified Momentum Watchlists - newser.com
Can you recover from losses in Aclaris Therapeutics Inc.Rate Cut & Safe Capital Growth Stock Tips - newser.com
Aclaris Therapeutics (NASDAQ:ACRS) adds US$40m to market cap in the past 7 days, though investors from three years ago are still down 83% - Yahoo Finance
How Aclaris Therapeutics Inc. stock trades before earningsWeekly Profit Report & Daily Stock Momentum Reports - newser.com
Is Aclaris Therapeutics Inc. stock a contrarian buy2025 Valuation Update & Fast Exit Strategy with Risk Control - newser.com
How to use a screener to detect Aclaris Therapeutics Inc. breakoutsJuly 2025 Big Picture & Expert Curated Trade Setup Alerts - newser.com
Will Aclaris Therapeutics Inc. benefit from macro trendsJuly 2025 Setups & Technical Confirmation Trade Alerts - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock a momentum leaderAnalyst Downgrade & Low Risk Profit Maximizing Plans - newser.com
What drives Aclaris Therapeutics Inc stock priceContrarian Investment Ideas & Investment Recommendations You Can Trust - earlytimes.in
Aclaris Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Will Aclaris Therapeutics Inc. (8AT) stock benefit from mergersQuarterly Performance Summary & Expert Curated Trade Ideas - newser.com
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 31% But Its Business Is Yet to Catch Up - 富途牛牛
Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 31% - simplywall.st
Aclaris Therapeutics’ ATI-045 Study: A Potential Game-Changer for Atopic Dermatitis - TipRanks
Will Aclaris Therapeutics Inc. stock outperform Dow Jones indexMarket Risk Analysis & Low Risk Investment Opportunities - newser.com
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aclaris Therapeutics Inc-Aktie (ACRS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):